List of Xerese drug patents

Xerese is owned by Bausch.

Xerese contains Acyclovir; Hydrocortisone.

Xerese has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Xerese are:

  • US7223387

Xerese was authorised for market use on 31 July, 2009.

Xerese is available in cream;topical dosage forms.

Xerese can be used as new combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).

The generics of Xerese are possible to be released after 13 November, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387 BAUSCH Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Nov, 2022

(2 months ago)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); Combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in